These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 18507782)
1. Mast cells are activated by Leishmania mexicana LPG and regulate the disease outcome depending on the genetic background of the host. Villaseñor-Cardoso MI; Salaiza N; Delgado J; Gutiérrez-Kobeh L; Pérez-Torres A; Becker I Parasite Immunol; 2008 Aug; 30(8):425-34. PubMed ID: 18507782 [TBL] [Abstract][Full Text] [Related]
2. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice. Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242 [TBL] [Abstract][Full Text] [Related]
3. Mast cells augment lesion size and persistence during experimental Leishmania major infection in the mouse. Wershil BK; Theodos CM; Galli SJ; Titus RG J Immunol; 1994 May; 152(9):4563-71. PubMed ID: 8157970 [TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan. Halliday A; Bates PA; Chance ML; Taylor MJ Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391 [TBL] [Abstract][Full Text] [Related]
5. Leishmania mexicana lipophosphoglycan differentially regulates PKCalpha-induced oxidative burst in macrophages of BALB/c and C57BL/6 mice. Delgado-Domínguez J; González-Aguilar H; Aguirre-García M; Gutiérrez-Kobeh L; Berzunza-Cruz M; Ruiz-Remigio A; Robles-Flores M; Becker I Parasite Immunol; 2010 Jun; 32(6):440-9. PubMed ID: 20500675 [TBL] [Abstract][Full Text] [Related]
6. NKT cell activation by Leishmania mexicana LPG: Description of a novel pathway. Zamora-Chimal J; Fernández-Figueroa EA; Ruiz-Remigio A; Wilkins-Rodríguez AA; Delgado-Domínguez J; Salaiza-Suazo N; Gutiérrez-Kobeh L; Becker I Immunobiology; 2017 Feb; 222(2):454-462. PubMed ID: 27523746 [TBL] [Abstract][Full Text] [Related]
7. Immunopathological studies of Leishmania amazonensis infection in resistant and in susceptible mice. de Oliveira Cardoso F; de Souza Cda S; Mendes VG; Abreu-Silva AL; Gonçalves da Costa SC; Calabrese KS J Infect Dis; 2010 Jun; 201(12):1933-40. PubMed ID: 20462353 [TBL] [Abstract][Full Text] [Related]
8. Mast cell degranulation contributes to susceptibility to Leishmania major. Romão PR; Da Costa Santiago H; Ramos CD; De Oliveira CF; Monteiro MC; De Queiroz Cunha F; Vieira LQ Parasite Immunol; 2009 Mar; 31(3):140-6. PubMed ID: 19222785 [TBL] [Abstract][Full Text] [Related]
9. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. Alexander J; Coombs GH; Mottram JC J Immunol; 1998 Dec; 161(12):6794-801. PubMed ID: 9862710 [TBL] [Abstract][Full Text] [Related]
10. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice. Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953 [TBL] [Abstract][Full Text] [Related]
11. Ceramide inhibits LPS-induced production of IL-5, IL-10, and IL-13 from mast cells. Chiba N; Masuda A; Yoshikai Y; Matsuguchi T J Cell Physiol; 2007 Oct; 213(1):126-36. PubMed ID: 17458900 [TBL] [Abstract][Full Text] [Related]
12. Monocyte cytokine and costimulatory molecule expression in patients infected with Leishmania mexicana. Carrada G; Cañeda C; Salaiza N; Delgado J; Ruiz A; Sanchez B; Gutiérrez-Kobeh L; Aguirre M; Becker I Parasite Immunol; 2007 Mar; 29(3):117-26. PubMed ID: 17266739 [TBL] [Abstract][Full Text] [Related]
13. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages. Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349 [TBL] [Abstract][Full Text] [Related]
14. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. Stamm LM; Räisänen-Sokolowski A; Okano M; Russell ME; David JR; Satoskar AR J Immunol; 1998 Dec; 161(11):6180-8. PubMed ID: 9834104 [TBL] [Abstract][Full Text] [Related]
15. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40. Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810 [TBL] [Abstract][Full Text] [Related]
16. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines. Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816 [TBL] [Abstract][Full Text] [Related]
17. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana. Torrentera FA; Glaichenhaus N; Laman JD; Carlier Y Infect Immun; 2001 Jan; 69(1):617-21. PubMed ID: 11119565 [TBL] [Abstract][Full Text] [Related]
18. Lack of signaling by IL-4 or by IL-4/IL-13 has more attenuating effects on Leishmania amazonensis dorsal skin--than on footpad-infected mice. Felizardo TC; Gaspar-Elsas MI; Lima GM; Abrahamsohn IA Exp Parasitol; 2012 Jan; 130(1):48-57. PubMed ID: 22019418 [TBL] [Abstract][Full Text] [Related]
19. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain. Alleva DG; Kaser SB; Beller DI J Immunol; 1998 Dec; 161(12):6878-84. PubMed ID: 9862720 [TBL] [Abstract][Full Text] [Related]
20. Mast cells at the host-pathogen interface: host-protection versus immune evasion in leishmaniasis. Saha B; Tonkal AM; Croft S; Roy S Clin Exp Immunol; 2004 Jul; 137(1):19-23. PubMed ID: 15196239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]